JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on IRD stock, giving a Buy rating today.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Debanjana Chatterjee has given his Buy rating due to a combination of factors surrounding Opus Genetics’ promising developments. The successful results from the Phase 3 VEGA-3 trial of Ryzumvi, which showed a significant benefit for presbyopia patients, are a key reason for optimism. Despite some limitations compared to competitors, Ryzumvi’s strong safety profile and expected future efficacy data bolster its competitive position.
Furthermore, the potential for label expansions and the promising pipeline of gene therapy assets, particularly the LCA5 program and OpGx-BEST1, are seen as major value drivers for the company. These advancements, along with anticipated updates and data releases, contribute to a positive outlook for Opus Genetics, justifying the Buy rating.
In another report released today, Craig-Hallum also assigned a Buy rating to the stock with a $6.00 price target.